liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Apoptosis and cancer: mutations within caspase genes
University of Manitoba, Winnipeg, Canada.
Zahedan University of Medical Sciences, Iran .
MICB, CancerCare Manitoba, Winnipeg, Canada.
St Boniface General Hospital Research Centre and University of Manitoba, Winnipeg, Canada.
Show others and affiliations
2009 (English)In: Journal of Medical Genetics, ISSN 0022-2593, E-ISSN 1468-6244, Vol. 46, no 8, 497-510 p.Article, review/survey (Refereed) Published
Abstract [en]

The inactivation of programmed cell death has profound effects not only on the development but also on the overall integrity of multicellular organisms. Beside developmental abnormalities, it may lead to tumorigenesis, autoimmunity, and other serious health problems. Deregulated apoptosis may also be the leading cause of cancer therapy chemoresistance. Caspase family of cysteinyl-proteases plays the key role in the initiation and execution of programmed cell death. This review gives an overview of the role of caspases, their natural modulators like IAPs, FLIPs, and Smac/Diablo in apoptosis and upon inactivation, and also in cancer development. Besides describing the basic mechanisms governing programmed cell death, a large part of this review is dedicated to previous studies that were focused on screening tumours for mutations within caspase genes as well as their regulators. The last part of this review discusses several emerging treatments that involve modulation of caspases and their regulators. Thus, we also highlight caspase cascade modulating experimental anticancer drugs like cFLIP-antagonist CDDO-Me; cIAP1 antagonists OSU-03012 and ME-BS; and XIAP small molecule antagonists 1396-11, 1396-12, 1396-28, triptolide, AEG35156, survivin/Hsp90 antagonist shephedrin, and some of the direct activators of procaspase-3.

Place, publisher, year, edition, pages
B M J Group , 2009. Vol. 46, no 8, 497-510 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-85190DOI: 10.1136/jmg.2009.066944ISI: 000268541500001PubMedID: 19505876OAI: oai:DiVA.org:liu-85190DiVA: diva2:566576
Available from: 2012-11-08 Created: 2012-11-08 Last updated: 2017-12-07

Open Access in DiVA

fulltext(346 kB)1814 downloads
File information
File name FULLTEXT01.pdfFile size 346 kBChecksum SHA-512
98bc2ef0706674333e7abb00c99867e8f4d44046d28f85b1c83c096ff204697b76d20f17455600c32a61224816407281cd9e153f61e6e9eba48e57d1115c5d2e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Wiechec, EmiliaLos, Marek

Search in DiVA

By author/editor
Wiechec, EmiliaLos, Marek
In the same journal
Journal of Medical Genetics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 1814 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 337 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf